Effect of in ovo administration of insulin-like growth factor-I on composition and mechanical properties of chicken bone.
The influence of in ovo administration of insulin-like growth factor-I (IGF-I) on long bone growth (tibiae and femora) of 42-d-old broiler chickens was investigated. Eggs were divided into three groups: uninjected control, vehicle-injected control, and recombinant human (rh) IGF-I. Eggs were injected once with 100 microL vehicle (10 mM acetic acid and 0.1% BSA) per embryo or vehicle containing 100 ng rh IGF-I/100 microL per embryo (n = 555 eggs total) on Days 1, 2, 3, or 4 of embryonic development. Males had greater bone length and moment of inertia than did females for the tibia and the femur (P < or = 0.01 for all). Although fracture load was significantly affected by gender (P < or = 0.02 and P < or = 0.006 for the femur and tibia, respectively), there was no treatment effect on these variables. However, when the fracture load was normalized with body weight of the animal, treatment and gender effects were found for femora (P < or = 0.04). Hydroxyproline concentrations of bones from male broilers were increased by the treatment (P < or = 0.02), whereas it had no effect on female broilers. There was no treatment effect on ash content, stiffness, yield load, yield deflection, and ultimate deflection and elastic, plastic, and total work for the femur or the tibia. We suggest that the effect of in ovo administration of IGF-I on bone mechanical properties was site-specific, and treated femora tended to have a lower fracture load relative to increased body weight.
Kocamis
H
H
Division of Animal and Veterinary Sciences, West Virginia University, Morgantown 26506, USA.
Yeni
Y N
YN
Brown
C U
CU
Kenney
P B
PB
Kirkpatrick-Keller
D C
DC
Killefer
J
J
D000818:Animals; D001696:Biomechanical Phenomena; D001842:Bone and Bones / Q000187:drug effects / Q000196:embryology* / Q000502:physiology; D002642:Chick Embryo / Q000187:drug effects*; D004548:Elasticity; D005260:Female; D005269:Femur / Q000737:chemistry / Q000502:physiology; D006909:Hydroxyproline / Q000032:analysis; D007267:Injections; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012727:Sex Characteristics; D013718:Tensile Strength; D013977:Tibia / Q000737:chemistry / Q000502:physiology
D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D006909:Hydroxyproline